BioCentury | Apr 15, 2013
Clinical News

Seragen regulatory update

...or persistent cutaneous T cell lymphoma (CTCL) despite prior therapy. (Phase III results, see B10) Seragen Inc....
BioCentury | Dec 6, 2004
Product Development

Accelerated approval history

...now Wyeth) 3 (142) Ontak denileukin diftitox Persistent or recurrent cutaneous T cell lymphoma 2/5/99 Seragen...
BioCentury | Jan 10, 2000
Company News

Ligand, Pharmaceutical Partners L.L.C. deal

...LGND's Seragen Inc. subsidiary (Hopkinton, Mass.) sold to Pharmaceutical Partners its royalty rights to Zenapax daclizumab antibody...
...organ transplant rejection, owned by Novartis AG (SWX:NOVN, Basel, Switzerland) (see BioCentury, Sept. 20, 1999). Seragen...
...million milestone if Zenapax sales achieve a certain level any year between 2001 and 2004. Seragen...
BioCentury | Sep 20, 1999
Company News

Ligand, Roche deal

...LGND subsidiary Seragen Inc. granted Roche a non-exclusive sublicense to its Strom Patents, which Seragen exclusively licensed...
...Protein Design Labs Inc. (PDLI, Fremont, Calif.), in the U.S., Canada, Australia and New Zealand. Seragen...
...beginning in Jan. 2001 will receive royalties on sales of Zenapax in the licensed territories. Seragen...
BioCentury | Aug 9, 1999
Company News

Ligand deal

...related to the $40 million worth of contingent merger obligations incurred with LGND's acquisition of Seragen Inc....
...and Marathon Biopharmaceuticals LLC (see BioCentury, Feb. 8). The payments reflect FDA marketing approval of Seragen's...
BioCentury | Feb 8, 1999
Company News

Ligand, Boston University deal

...Ontak , a fusion protein to treat cutaneous T cell lymphoma developed by LGND subsidiary Seragen Inc....
BioCentury | Feb 8, 1999
Clinical News

Ligand regulatory update

...T cell lymphomas that express the CD25 component of the interleukin-2 receptor . LGND subsidiary Seragen Inc....
BioCentury | Jan 4, 1999
Company News

Ligand cancer, metabolic news

...Certain shareholders of LGND subsidiary Seragen Inc. (Hopkinton, Mass.) filed an amended suit in the Court of...
...by Seragen directors and officers. The original complaint sought to prevent LGND's 1998 acquisition of Seragen...
BioCentury | Nov 9, 1998
Emerging Company Profile

Angiogene: Antiproliferative radiation

...Inc. (TSE:ANP, Vancouver, B.C.) uses the cancer drug paclitaxel formulated in plastics to coat stents. Seragen Inc....
BioCentury | Oct 5, 1998
Finance

Third Quarter Stocks: If not now, . . .

...was Seragen Inc. (Hopkinton, Mass.), which was purchased by Ligand Pharmaceuticals Inc. (LGND, San Diego, Calif.). Seragen's...
Items per page:
1 - 10 of 70
BioCentury | Apr 15, 2013
Clinical News

Seragen regulatory update

...or persistent cutaneous T cell lymphoma (CTCL) despite prior therapy. (Phase III results, see B10) Seragen Inc....
BioCentury | Dec 6, 2004
Product Development

Accelerated approval history

...now Wyeth) 3 (142) Ontak denileukin diftitox Persistent or recurrent cutaneous T cell lymphoma 2/5/99 Seragen...
BioCentury | Jan 10, 2000
Company News

Ligand, Pharmaceutical Partners L.L.C. deal

...LGND's Seragen Inc. subsidiary (Hopkinton, Mass.) sold to Pharmaceutical Partners its royalty rights to Zenapax daclizumab antibody...
...organ transplant rejection, owned by Novartis AG (SWX:NOVN, Basel, Switzerland) (see BioCentury, Sept. 20, 1999). Seragen...
...million milestone if Zenapax sales achieve a certain level any year between 2001 and 2004. Seragen...
BioCentury | Sep 20, 1999
Company News

Ligand, Roche deal

...LGND subsidiary Seragen Inc. granted Roche a non-exclusive sublicense to its Strom Patents, which Seragen exclusively licensed...
...Protein Design Labs Inc. (PDLI, Fremont, Calif.), in the U.S., Canada, Australia and New Zealand. Seragen...
...beginning in Jan. 2001 will receive royalties on sales of Zenapax in the licensed territories. Seragen...
BioCentury | Aug 9, 1999
Company News

Ligand deal

...related to the $40 million worth of contingent merger obligations incurred with LGND's acquisition of Seragen Inc....
...and Marathon Biopharmaceuticals LLC (see BioCentury, Feb. 8). The payments reflect FDA marketing approval of Seragen's...
BioCentury | Feb 8, 1999
Company News

Ligand, Boston University deal

...Ontak , a fusion protein to treat cutaneous T cell lymphoma developed by LGND subsidiary Seragen Inc....
BioCentury | Feb 8, 1999
Clinical News

Ligand regulatory update

...T cell lymphomas that express the CD25 component of the interleukin-2 receptor . LGND subsidiary Seragen Inc....
BioCentury | Jan 4, 1999
Company News

Ligand cancer, metabolic news

...Certain shareholders of LGND subsidiary Seragen Inc. (Hopkinton, Mass.) filed an amended suit in the Court of...
...by Seragen directors and officers. The original complaint sought to prevent LGND's 1998 acquisition of Seragen...
BioCentury | Nov 9, 1998
Emerging Company Profile

Angiogene: Antiproliferative radiation

...Inc. (TSE:ANP, Vancouver, B.C.) uses the cancer drug paclitaxel formulated in plastics to coat stents. Seragen Inc....
BioCentury | Oct 5, 1998
Finance

Third Quarter Stocks: If not now, . . .

...was Seragen Inc. (Hopkinton, Mass.), which was purchased by Ligand Pharmaceuticals Inc. (LGND, San Diego, Calif.). Seragen's...
Items per page:
1 - 10 of 70